Canada first country to approve cannabis based painkiller Canada has become the first country to approve a cannabis based painkiller for multiple sclerosis patients. The spray, Sativex, which is derived from the marijuana plant, went on sale in Canada on Monday. You’ll be able to obtain Sativex by prescription through Canadian pharmacies now. British drug business GW Pharmaceuticals, created the medication which can be marketed in Canada by Bayer HealthCare. Health Canada, the federal government agency that oversees health care for Canadians, approved Sativex in April. Sativex is made from components produced from the cannabis plant which have been proven to ease pain. Related StoriesNew review discovers scant scientific proof supporting use of cannabinoids in rheumatic diseasesCannabis and Cannabinoid Study journal helps President Obama's statement on medical use of marijuanaMen much more likely to suffer from cannabis psychosis compared to womenIn general the medical profession has welcomed the availability of the drug.Not surprisingly promise, therapeutic tumor vaccine developers have not yet realized the entire potential of the new class of malignancy treatment. Two years ago, the Cancer Research Institute conducted an analysis of the field and recognized two major challenges to the speedy development of tumor vaccines: cancers vaccines present myriad development complexities because they must incorporate multiple elements that action in synergy to achieve optimal efficacy against malignancy; and there exists a significant and developing funding gap for early phase clinical trials, particularly for treatment modalities that are perceived as more technical or riskier than standard, such as cancer tumor immunotherapy.